These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38402253)

  • 41. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Chen MH; Cheng CM; Li CT; Tsai SJ; Lin WC; Bai YM; Su TP
    Psychiatry Res; 2022 Oct; 316():114749. PubMed ID: 35940087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.
    Sydnor VJ; Lyall AE; Cetin-Karayumak S; Cheung JC; Felicione JM; Akeju O; Shenton ME; Deckersbach T; Ionescu DF; Pasternak O; Cusin C; Kubicki M
    Transl Psychiatry; 2020 Dec; 10(1):432. PubMed ID: 33319774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
    Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
    Nugent AC; Wills KE; Gilbert JR; Zarate CA
    Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
    Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ketamine: Future Treatment For Unresponsive Depression?
    Frere M; Tepper J
    Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a randomized controlled trial.
    Rengasamy M; Mathew S; Howland R; Griffo A; Panny B; Price R
    EBioMedicine; 2024 Jan; 99():104902. PubMed ID: 38141395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
    Veldman ER; Mamula D; Jiang H; Tiger M; Ekman CJ; Lundberg J; Svenningsson P
    J Affect Disord; 2021 Jul; 290():240-244. PubMed ID: 34010748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression.
    Taraku B; Woods RP; Boucher M; Espinoza R; Jog M; Al-Sharif N; Narr KL; Zavaliangos-Petropulu A
    Hum Brain Mapp; 2023 Apr; 44(6):2395-2406. PubMed ID: 36715291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression.
    Yonezawa K; Uchida H; Yatomi T; Ohtani Y; Nomoto-Takahashi K; Nakajima S; Mimura M; Tani H
    Pharmacopsychiatry; 2024 Jan; 57(1):35-40. PubMed ID: 37846462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
    [No Abstract]   [Full Text] [Related]  

  • 56. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
    Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
    Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ketamine: Leading us into the future for development of antidepressants.
    Carreno FR; Lodge DJ; Frazer A
    Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
    McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW
    Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized placebo-controlled PET study of ketamine´s effect on serotonin
    Tiger M; Veldman ER; Ekman CJ; Halldin C; Svenningsson P; Lundberg J
    Transl Psychiatry; 2020 Jun; 10(1):159. PubMed ID: 32475989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression.
    Zhang F; Wang C; Lan X; Li W; Ye Y; Liu H; Hu Z; You Z; Zhou Y; Ning Y
    J Affect Disord; 2023 Mar; 325():534-541. PubMed ID: 36646174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.